Efficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats
Journal of Veterinary Internal Medicine · 01.07.2024 · 38 (4) · 2099-2119
DOI: 10.1111/jvim.17124 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, online erschienen am 01.07.2024. Verfasst von Stijn J M Niessen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Veterinary Specialist Consultations & VIN Europe, Hilversum, The Netherlands. Hauptthemen laut MEDLINE: Cat Diseases, Hypoglycemic Agents, Insulin, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boehringer Ingelheim Animal Health.
Abstract (Originalsprache)
Background
Options for treatment of diabetes mellitus in cats are limited to insulin injections and monitoring for hypoglycemia. Hypothesis Once daily sodium-glucose cotransporter-2 inhibitor velagliflozin PO is noninferior to insulin injections. Animals Client-owned diabetic cats (127 safety; 116 efficacy assessment).
Methods
Prospective, randomized (1 mg/kg velagliflozin), positive controlled (titrated Caninsulin), open label, noninferiority field trial, comparing number of cats with treatment success in ≥1 clinical variable and ≥1 glycemic variable (margin Δ: 15%) on Day 45; secondary endpoints included glycemic and clinical assessments during 91 days.
Results
On Day 45, 29/54 (54%) velagliflozin-treated cats and 26/62 (42%) Caninsulin-treated cats showed treatment success, demonstrating noninferiority (difference −11.8%; upper 1-sided 97.5% confidence interval, −∞ to 6.3%). By Day 91, quality of life (QoL), polyuria, and polydipsia had improved in 81%, 54% and 61% (velagliflozin); on blood glucose (BG) curves, mean BG was <252 mg/dL in 42/54 (78%; velagliflozin) and 37/62 (60%; Caninsulin); minimum BG was <162 mg/dL in 41/54 (76%; velagliflozin) and 41/62 (66%; Caninsulin); serum fructosamine was <450 μmol/L in 41/54 (76%; velagliflozin) and 38/62 (61%; Caninsulin). Velagliflozin's most frequent adverse events were loose feces/diarrhea (n = 23/61, 38%), positive urine culture (n = 19/61, 31%), and nonclinical hypoglycemia (BG <63 mg/dL; n = 8/61, 13%); Caninsulin's: clinical and nonclinical hypoglycemia (n = 35/66, 53%), positive urine culture (n = 18/66, 27%), and loose feces/diarrhea (n = 10/66, 15%). Diabetic ketoacidosis occurred in 4/61 (7%; velagliflozin) and 0/66 (Caninsulin). Conclusions and Clinical Importance Once daily oral administration of velagliflozin was noninferior to insulin injections, showed good QoL and glycemia without clinical hypoglycemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Veterinary Specialist Consultations & VIN Europe, Hilversum, The Netherlands.
- Royal Veterinary College, University of London, Hertfordshire, United Kingdom.
- Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
- Bjørnvad Consultancy, Vedbæk, Denmark.
- Boehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein, Germany.
ORCID-Profile: Stijn J M Niessen, Charlotte R Bjørnvad, Balazs Albrecht
Förderung
- Boehringer Ingelheim Animal Health
Zitieren
APA
Niessen, S. J. M., Kooistra, H. S., Forcada, Y., Bjørnvad, C. R., Albrecht, B., Roessner, F., Herberich, E., & Kroh, C. (2024). Efficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats. Journal of Veterinary Internal Medicine, 38(4), 2099-2119. https://doi.org/10.1111/jvim.17124
Vancouver
Niessen SJM, Kooistra HS, Forcada Y, Bjørnvad CR, Albrecht B, Roessner F, et al. Efficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats. Journal of Veterinary Internal Medicine. 2024;38(4):2099-2119. doi:10.1111/jvim.17124
BibTeX
@article{Niessen2024,
author = {Niessen, Stijn J M and Kooistra, Hans S and Forcada, Yaiza and Bjørnvad, Charlotte R and Albrecht, Balazs and Roessner, Franziska and Herberich, Esther and Kroh, Carla},
title = {Efficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats},
journal = {Journal of Veterinary Internal Medicine},
year = {2024},
volume = {38},
number = {4},
pages = {2099--2119},
doi = {10.1111/jvim.17124}
}
EUVIMED